We serve Chemical Name:5-[3-(trifluoromethyl)phenyl]-1H-pyrazol-3-amine CAS:209224-91-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![5-[3-(trifluoromethyl)phenyl]-1H-pyrazol-3-amine](https://a.dearchem.com/CAS2/209224-91-9.png)
Chemical Name:5-[3-(trifluoromethyl)phenyl]-1H-pyrazol-3-amine
CAS.NO:209224-91-9
Synonyms:5-Amino-3-[3-(trifluoromethyl)phenyl]-1H-pyrazole;5-(3-TRIFLUOROMETHYL-PHENYL)-2H-PYRAZOL-3-YLAMINE;3-(3-(TRIFLUOROMETHYL)PHENYL)-1H-PYRAZOL-5-AMINE
Molecular Formula:C10H8F3N3
Molecular Weight:227.18600
HS Code:
Physical and Chemical Properties:
Melting point:130-132ºC
Boiling point:425.1ºC at 760 mmHg
Density:1.401g/cm3
Index of Refraction:1.562
PSA:54.70000
Exact Mass:227.06700
LogP:3.25890
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 5-Amino-3-[3-(trifluoromethyl)phenyl]-1H-pyrazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-(3-(TRIFLUOROMETHYL)PHENYL)-1H-PYRAZOL-5-AMINE physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-(3-(TRIFLUOROMETHYL)PHENYL)-1H-PYRAZOL-5-AMINE Use and application,5-Amino-3-[3-(trifluoromethyl)phenyl]-1H-pyrazole technical grade,usp/ep/jp grade.
Related News: But even though weight-loss success depends on adopting a challenging” change in post-operation diet and lifestyle, the process can certainly “help people to lose weight and get comorbid [other negative health] conditions under better control,” Sandon said.
So it’s important, she said, to help eligible patients better “understand the treatment options and potential for success,” by sharing surgery success stories and highlighting the benefits of reducing high-risk health issues such as blood pressure and diabetes.
An experimental Alzheimer’s vaccine appears to safely clear abnormal tau protein from the brain, but it’s not yet clear whether the shot will be able to save brain function.
In a Phase 2 clinical trial, the vaccine produced high levels of antibodies to target and attack free-floating tau proteins before they can form “tau tangles” that clog neurons and damage brain function. Tau tangles, along with plaques formed by the protein amyloid-beta, serve as one of the main hallmarks of Alzheimer’s.
“While amyloid influences speed of Alzheimer’s progression, there is strong evidence that tau pathology relates to the underlying cause of the disease,” said lead researcher Dr. Petr Novak, a senior clinical research scientist at AXON Neuroscience, the Slovakian pharmaceutical company developing the vaccine. “Brain atrophy and cognitive loss closely echo the deposition of pathological tau protein, as evidenced by recent tau PET studies. 5-[3-(trifluoromethyl)phenyl]-1H-pyrazol-3-amine manufacturer But even though weight-loss success depends on adopting a challenging” change in post-operation diet and lifestyle, the process can certainly “help people to lose weight and get comorbid [other negative health] conditions under better control,” Sandon said.
So it’s important, she said, to help eligible patients better “understand the treatment options and potential for success,” by sharing surgery success stories and highlighting the benefits of reducing high-risk health issues such as blood pressure and diabetes.
An experimental Alzheimer’s vaccine appears to safely clear abnormal tau protein from the brain, but it’s not yet clear whether the shot will be able to save brain function.
In a Phase 2 clinical trial, the vaccine produced high levels of antibodies to target and attack free-floating tau proteins before they can form “tau tangles” that clog neurons and damage brain function. Tau tangles, along with plaques formed by the protein amyloid-beta, serve as one of the main hallmarks of Alzheimer’s.
“While amyloid influences speed of Alzheimer’s progression, there is strong evidence that tau pathology relates to the underlying cause of the disease,” said lead researcher Dr. Petr Novak, a senior clinical research scientist at AXON Neuroscience, the Slovakian pharmaceutical company developing the vaccine. “Brain atrophy and cognitive loss closely echo the deposition of pathological tau protein, as evidenced by recent tau PET studies. 5-[3-(trifluoromethyl)phenyl]-1H-pyrazol-3-amine supplier Our collaboration with Mankind demonstrates our commitment towards providing novel, innovative treatment options for efficient diabetes management, Glenmark Pharmaceuticals President, India Formulations, Middle East and Africa Sujesh Vasudevan said. 5-[3-(trifluoromethyl)phenyl]-1H-pyrazol-3-amine vendor Our collaboration with Mankind demonstrates our commitment towards providing novel, innovative treatment options for efficient diabetes management, Glenmark Pharmaceuticals President, India Formulations, Middle East and Africa Sujesh Vasudevan said. 5-[3-(trifluoromethyl)phenyl]-1H-pyrazol-3-amine factory But even though weight-loss success depends on adopting a challenging” change in post-operation diet and lifestyle, the process can certainly “help people to lose weight and get comorbid [other negative health] conditions under better control,” Sandon said.
So it’s important, she said, to help eligible patients better “understand the treatment options and potential for success,” by sharing surgery success stories and highlighting the benefits of reducing high-risk health issues such as blood pressure and diabetes.
An experimental Alzheimer’s vaccine appears to safely clear abnormal tau protein from the brain, but it’s not yet clear whether the shot will be able to save brain function.
In a Phase 2 clinical trial, the vaccine produced high levels of antibodies to target and attack free-floating tau proteins before they can form “tau tangles” that clog neurons and damage brain function. Tau tangles, along with plaques formed by the protein amyloid-beta, serve as one of the main hallmarks of Alzheimer’s.
“While amyloid influences speed of Alzheimer’s progression, there is strong evidence that tau pathology relates to the underlying cause of the disease,” said lead researcher Dr. Petr Novak, a senior clinical research scientist at AXON Neuroscience, the Slovakian pharmaceutical company developing the vaccine. “Brain atrophy and cognitive loss closely echo the deposition of pathological tau protein, as evidenced by recent tau PET studies.
So it’s important, she said, to help eligible patients better “understand the treatment options and potential for success,” by sharing surgery success stories and highlighting the benefits of reducing high-risk health issues such as blood pressure and diabetes.
An experimental Alzheimer’s vaccine appears to safely clear abnormal tau protein from the brain, but it’s not yet clear whether the shot will be able to save brain function.
In a Phase 2 clinical trial, the vaccine produced high levels of antibodies to target and attack free-floating tau proteins before they can form “tau tangles” that clog neurons and damage brain function. Tau tangles, along with plaques formed by the protein amyloid-beta, serve as one of the main hallmarks of Alzheimer’s.
“While amyloid influences speed of Alzheimer’s progression, there is strong evidence that tau pathology relates to the underlying cause of the disease,” said lead researcher Dr. Petr Novak, a senior clinical research scientist at AXON Neuroscience, the Slovakian pharmaceutical company developing the vaccine. “Brain atrophy and cognitive loss closely echo the deposition of pathological tau protein, as evidenced by recent tau PET studies. 5-[3-(trifluoromethyl)phenyl]-1H-pyrazol-3-amine manufacturer But even though weight-loss success depends on adopting a challenging” change in post-operation diet and lifestyle, the process can certainly “help people to lose weight and get comorbid [other negative health] conditions under better control,” Sandon said.
So it’s important, she said, to help eligible patients better “understand the treatment options and potential for success,” by sharing surgery success stories and highlighting the benefits of reducing high-risk health issues such as blood pressure and diabetes.
An experimental Alzheimer’s vaccine appears to safely clear abnormal tau protein from the brain, but it’s not yet clear whether the shot will be able to save brain function.
In a Phase 2 clinical trial, the vaccine produced high levels of antibodies to target and attack free-floating tau proteins before they can form “tau tangles” that clog neurons and damage brain function. Tau tangles, along with plaques formed by the protein amyloid-beta, serve as one of the main hallmarks of Alzheimer’s.
“While amyloid influences speed of Alzheimer’s progression, there is strong evidence that tau pathology relates to the underlying cause of the disease,” said lead researcher Dr. Petr Novak, a senior clinical research scientist at AXON Neuroscience, the Slovakian pharmaceutical company developing the vaccine. “Brain atrophy and cognitive loss closely echo the deposition of pathological tau protein, as evidenced by recent tau PET studies. 5-[3-(trifluoromethyl)phenyl]-1H-pyrazol-3-amine supplier Our collaboration with Mankind demonstrates our commitment towards providing novel, innovative treatment options for efficient diabetes management, Glenmark Pharmaceuticals President, India Formulations, Middle East and Africa Sujesh Vasudevan said. 5-[3-(trifluoromethyl)phenyl]-1H-pyrazol-3-amine vendor Our collaboration with Mankind demonstrates our commitment towards providing novel, innovative treatment options for efficient diabetes management, Glenmark Pharmaceuticals President, India Formulations, Middle East and Africa Sujesh Vasudevan said. 5-[3-(trifluoromethyl)phenyl]-1H-pyrazol-3-amine factory But even though weight-loss success depends on adopting a challenging” change in post-operation diet and lifestyle, the process can certainly “help people to lose weight and get comorbid [other negative health] conditions under better control,” Sandon said.
So it’s important, she said, to help eligible patients better “understand the treatment options and potential for success,” by sharing surgery success stories and highlighting the benefits of reducing high-risk health issues such as blood pressure and diabetes.
An experimental Alzheimer’s vaccine appears to safely clear abnormal tau protein from the brain, but it’s not yet clear whether the shot will be able to save brain function.
In a Phase 2 clinical trial, the vaccine produced high levels of antibodies to target and attack free-floating tau proteins before they can form “tau tangles” that clog neurons and damage brain function. Tau tangles, along with plaques formed by the protein amyloid-beta, serve as one of the main hallmarks of Alzheimer’s.
“While amyloid influences speed of Alzheimer’s progression, there is strong evidence that tau pathology relates to the underlying cause of the disease,” said lead researcher Dr. Petr Novak, a senior clinical research scientist at AXON Neuroscience, the Slovakian pharmaceutical company developing the vaccine. “Brain atrophy and cognitive loss closely echo the deposition of pathological tau protein, as evidenced by recent tau PET studies.
